- Home
- RMTI vs DMAC Comparison
RMTI vs DMAC Comparison
Compare RMTI & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMTI
- DMAC
- Stock Information
- Founded
- RMTI 1994
- DMAC 2000
- Country
- RMTI United States
- DMAC United States
- Employees
- RMTI N/A
- DMAC N/A
- Industry
- RMTI Biotechnology: Pharmaceutical Preparations
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- RMTI Health Care
- DMAC Health Care
- Exchange
- RMTI Nasdaq
- DMAC Nasdaq
- Market Cap
- RMTI 32.5M
- DMAC 178.0M
- IPO Year
- RMTI 1998
- DMAC N/A
- Fundamental
- Price
- RMTI $1.15
- DMAC $3.63
- Analyst Decision
- RMTI Strong Buy
- DMAC Strong Buy
- Analyst Count
- RMTI 2
- DMAC 2
- Target Price
- RMTI $4.00
- DMAC $8.00
- AVG Volume (30 Days)
- RMTI 418.1K
- DMAC 325.9K
- Earning Date
- RMTI 08-07-2025
- DMAC 08-06-2025
- Dividend Yield
- RMTI N/A
- DMAC N/A
- EPS Growth
- RMTI N/A
- DMAC N/A
- EPS
- RMTI N/A
- DMAC N/A
- Revenue
- RMTI $97,727,000.00
- DMAC N/A
- Revenue This Year
- RMTI N/A
- DMAC N/A
- Revenue Next Year
- RMTI $11.16
- DMAC N/A
- P/E Ratio
- RMTI N/A
- DMAC N/A
- Revenue Growth
- RMTI 12.82
- DMAC N/A
- 52 Week Low
- RMTI $0.78
- DMAC $2.98
- 52 Week High
- RMTI $5.15
- DMAC $6.82
- Technical
- Relative Strength Index (RSI)
- RMTI 74.79
- DMAC 44.55
- Support Level
- RMTI $0.80
- DMAC $3.48
- Resistance Level
- RMTI $0.87
- DMAC $3.88
- Average True Range (ATR)
- RMTI 0.08
- DMAC 0.26
- MACD
- RMTI 0.05
- DMAC 0.00
- Stochastic Oscillator
- RMTI 79.69
- DMAC 30.10
About RMTI Rockwell Medical Inc.
Rockwell Medical Inc is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers. It is a supplier of liquid bicarbonate concentrates, and acid and dry bicarbonate concentrates for dialysis patients in the United States. The company's products include CitraPure citric acid concentrate, RenalPure liquid acid concentrate, and SteriLyte bicarbonate concentrate among others.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.